Drug Maker Amneal Highlights Strong Commercial Uptake For Parkinson's Drug But Q1 Earnings Are Mixed
benzinga.com/general/health-care/25/05/45175642/drug-maker-amneal-highlights-strong-commercial-uptake-for-parkinsons-drug-but-q1-earnings-are
Amneal Pharmaceuticals Inc. (NASDAQ:AMRX) reported first-quarter 2025 adjusted EPS of 21 cents, up from 14 cents a year ago, and beating the consensus of 15 cents.
The company reported sales of $695.42 million, up 5% year-over-year, missing the consensus of $715.49 million.
Affordable…
This story appeared on benzinga.com, 2025-05-02 18:22:21.